Crioablazione e Sorafenib

Link all'articolo.

Grandi speranze e importanti conferme della utilità della crioablazione dei tumori solidi.

"Cryoablation increases the clinical efficacy of treatment with the oral multi-target antitumour drug sorafenib for advanced renal cell carcinoma (RCC), a new study published in the International Journal of Hyperthermia has found. Joint first authors Changfu Liu and Fei Cao (both Department for Interventional Treatment, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China) conclude that combining cryoablation with sorafenib can reduce tumour load, improve anti-tumour immunosuppressive status, increase survival, and maintain quality of life in patients with RCC that cannot be surgically resected."